ClinicalTrials.gg
RecruitingNCT05942625Updated Oct 9, 2024

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

A Phase 1 interventional study of HS-10390 tablet and Placebo tablet in IgA Nephropathy and Focal Segmental Glomerulosclerosis, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
54th of 109
84 · median 84
Started
2023
with 10 others
Phase 1
21 of 127
13 open now
Primary completion
2024-06
later than 1 of 72 live
Registered
65th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 54th largest by planned enrollment of the 109 interventional ones that give a count, is one of 11 that started in 2023, is one of 21 in phase 1, reaches primary completion later than 1 of the 72 other live ones, and was the 65th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascendingdose (SAD and MAD) study to evaluate the safety, tolerability, PK, and PD of different doses of HS-10390 tablet(s) in healthy subjects. During the SAD and MAD periods, there will be approximately 6and 3 sequential cohorts respectively. A sentinel dosing strategy will be used in the first cohort ofSAD. The MAD study will start after sufficient safety and PK data of SAD period are obtained.

03

Conditions studied

  • IgA Nephropathy
  • Focal Segmental Glomerulosclerosis

Keywords

  • HS-10390
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Pharmacodynamics
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects between the ages of 18-45 years
  • Have no ; or agree to use a highly effective method ofcontraception, and refrain from donating sperm or eggs during the study period and forat least 6 months after last dosing
  • Have signed the form approved by the IRB

Exclusion criteria

Exclusion Criteria:

  • History or evidence of cardiovascular, pulmonary, endocrine,gastrointestinal, psychiatric, neurologic, hematological or metabolic diseases, especiallythose conditions that interfere with absorption, metabolism and/or excretion of the studydrug, determined by the investigator
  • Have a clinically significant infection currently or within past 30 days, or have a history ofactive tuberculosis; or have positive screening test for infectious disease, includingtuberculosis, viral hepatitis, AIDS and syphilis
  • Have a history of or current allergic disease
  • Have a history of drug or alcohol abuse or currently positive test result(s) for alcohol ordrugs of abuse
  • Smokers smoked ≥5 cigarettes per day within past 3 months or have a positive test resultfor nicotine
  • Clinically significant abnormal physical examination, vital signs, clinical laboratory values,ECGs or imaging tests
  • Pregnant or breastfeeding female subjects
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    HS-10390

    Single or multiple dosing of HS-10390 in a fastingstate

    Drug: HS-10390 tablet

  • Experimental
    Placebo

    Single or multiple dosing of placebo in a fastingstate

    Drug: Placebo tablet

Interventions

  • Oral administration of specified dose of HS-10390

  • DrugPlacebo tablet

    Oral administration of matching dose ofplacebo

06

What researchers measure

Primary outcomes

  1. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation

    Time frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 28 (MAD)

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  2. Time to reach Cmax (Tmax)

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  3. Area under the plasma concentration-time curve from time zero to time t (AUC0-t)

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  4. Half time (t½)

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  5. Apparent clearance (CL/F)

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  6. Apparent volume of distribution (Vz/F)

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  7. Accumulation ratio(Rac)

    Time frame: Day 14 up to Day 19 (MAD)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jun 2024, 13 months.

Of 22 phase 1 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 13 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2023
First posted
Jul 12, 2023
StartActual
May 23, 2023
Primary completionActual
Jun 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05942625
Responsible party
Sponsor
First posted
Jul 12, 2023
Start date
May 23, 2023
Primary completion
Jun 30, 2024
Completion
Dec 30, 2024 (estimated)
Last update
Oct 9, 2024

Study contacts

Bicheng Liu
Contact
liubc64@163.com
18001580838

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10390

Start the discussion